StageZero Life Sciences Ltd.

Equities

SZLS

CA8525403017

Biotechnology & Medical Research

Market Closed - Toronto S.E. Other stock markets 16:00:00 16/04/2024 BST			5-day change	1st Jan Change
0.04 ^CAD	-.--%		-.--%	-11.11%

05-21	Transcript : StageZero Life Sciences Ltd., Q1 2024 Earnings Call, May 21, 2024
05-16	StageZero Life Sciences Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

StageZero Life Sciences Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024

May 16, 2024 at 04:04 am

StageZero Life Sciences Ltd. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported sales was USD 0.521921 million compared to USD 0.778515 million a year ago. Net loss was USD 0.386349 million compared to USD 1.81 million a year ago.

Latest news about StageZero Life Sciences Ltd.

Transcript : StageZero Life Sciences Ltd., Q1 2024 Earnings Call, May 21, 2024	05-21
StageZero Life Sciences Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-16	CI
North American Morning Briefing : Stock Futures -2-	04-11	DJ
North American Morning Briefing : Focus Turns to -2-	04-04	DJ
North American Morning Briefing : All Eyes on -2-	11-21	DJ
Transcript : StageZero Life Sciences Ltd., Q3 2023 Earnings Call, Nov 15, 2023	11-15
StageZero Life Sciences Ltd. Partners with My One Medical Source and 1,000+ Medical Access Points in the USA	11-14	CI
StageZero Life Sciences Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13	CI
StageZero Life Sciences, Ltd. Clinical Business Introduces Fourth Pillar to Cancer Offerings	11-07	CI
StageZero Life Sciences	20/10/23	MT
Stagezero Life Sciences, Ltd. Clinical Business Introduces Third Pillar to Cancer Offerings	20/10/23	CI
North American Morning Briefing : Stock Futures -2-	22/08/23	DJ
Transcript : StageZero Life Sciences Ltd., Q2 2023 Earnings Call, Aug 15, 2023	15/08/23
StageZero Life Sciences Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	13/08/23	CI
Transcript : StageZero Life Sciences Ltd. - Shareholder/Analyst Call	07/06/23
Transcript : StageZero Life Sciences Ltd., Q1 2023 Earnings Call, May 16, 2023	16/05/23
North American Morning Briefing : Retail Sales, -2-	16/05/23	DJ
StageZero Life Sciences Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	14/05/23	CI
Transcript : StageZero Life Sciences Ltd., Q4 2022 Earnings Call, Apr 03, 2023	03/04/23
StageZero Life Sciences Ltd. Auditor Raises 'Going Concern' Doubt	30/03/23	CI
StageZero Life Sciences Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	30/03/23	CI
StageZero Life Sciences Says Secured C$25 Million Capital Commitment from GEM Global Yield LLC SCS	21/11/22	MT
StageZero Life Sciences Brief: Says Secured C$25 Million Capital Commitment from GEM Global Yield LLC SCS	21/11/22	MT
Transcript : StageZero Life Sciences Ltd., Q3 2022 Earnings Call, Nov 15, 2022	15/11/22
North American Morning Briefing : Positive China -2-	15/11/22	DJ

Chart StageZero Life Sciences Ltd.

Duration

Period

More charts

Company Profile

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is focused on improving the early detection and management of cancer and other chronic diseases through diagnostics telehealth programs. Its lead product, Aristotle, is a mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. The Care Oncology Clinic offers a supervised treatment regimen for people diagnosed with cancer of any type or stage. AVRT is a physician-led, telehealth program for identifying and managing the early warning signs of cancer and chronic disease. Its program includes a comprehensive online health evaluation; bloodtests to measure markers of inflammation and metabolism; an initial physician consultation; regular physician follow-up appointments and interval screening. Its additional cancer diagnostics include ColonSentry and the Prostate Health Index.

Sector

Biotechnology & Medical Research

Calendar

12/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
STAGEZERO LIFE SCIENCES LTD.	-11.11%	3.62M
MODERNA, INC.	+43.36%	54.63B
IQVIA HOLDINGS INC.	-5.31%	39.92B
LONZA GROUP AG	+37.52%	38.82B
ICON PUBLIC LIMITED COMPANY	+14.75%	26.86B
CELLTRION, INC.	-12.56%	26.22B
ALNYLAM PHARMACEUTICALS, INC.	-22.45%	18.78B
UNITED THERAPEUTICS CORPORATION	+25.12%	12.21B
BIO-TECHNE CORPORATION	+0.04%	12.16B
MEDPACE HOLDINGS, INC.	+26.04%	11.94B

Other Biotechnology & Medical Research